




FIG. 1





BINDING INHIBITION








DIMBINIO INTERPRETARI




















FIG.5C

INTERLEUKINE-2 RECEPTOR









FIG. 6A











































ACTIVITY	‡	#	ı	1	ı	9	+	
MAIN MOLECULAR SPECIES	TETRAMER (4M-8M, Kd=30-100 pm) /OCTAMER	DIMER (1M-2M,Kd=0,2µM) /TETRAMER (2M-4M,Kd=100µM)		(1M-2M,Kd=50µM) (2M-4M,Kd=1,4mM)	(1M-2M,Kd=113µM)	æ	2 4	
MAIN M	TETRAMER (/OCTAMER	DIMER /Tetra		DIMER	DIMER	MONOMER	MONOMER	10
% HELIX (CIRCULAR DICHROISM)	50% (150 @ 30µM) 35% (4µM)	22% (150 @ 30µM)	<2%	%0	%0	%0	~5%	DIC 10
1 10 20 30 30 APTISSSTKKTQLQLEHLLLDLQMILNGINN	30	10 30	22	10	5 15	10 20	20 20	
-	 			 				



IP130

FIG. 11A




IP130

FIG. 11B

(


BLOT 4G10 (ANTI PHOSPHOTYROSINE)




NO STIMULATION IL - 2 (IO MIN)

IP 130(1 MIN)
IP 130(2 MIN)
IP 130(5 MIN)
IP 130(10 MIN)
IP 130(15 MIN)


F I G .12 A






ACTIVATED STATS

9 FIG.13







NK CELLS (CD56 $^+$) ENTERING IN S+G2/M PHASES AFTER IP130 STIMULATION (SYNERGY WITH IL-2)

TREAT	IMEN	T		J31	J32	J33
IL-2 50 nM				. 14	12	14
		IP130	60 <i>µ</i> M	0	17	≤5
		IP130	120 <i>μ</i> Μ	0	14	<5
IL-2 50 nM	+	IP130	60 <i>μ</i> Μ	26	21	7
IL-2 50 nM	+	IP130	120µM	28	28	28

FIG. 15







STIMULATION 6 DAYS

9

8







\$


20


8

SISJ7% 7












FIG. 19